TuHURA Biosciences (HURA) Change in Account Payables (2010 - 2024)
TuHURA Biosciences (HURA) posted quarterly Change in Account Payables of -$4000.0 for Q3 2024, down 110.0% year-over-year from $40000.0 in Q4 2023, and up 98.0% quarter-over-quarter from -$200000.0 in Q1 2024.
TuHURA Biosciences (HURA) Change in Account Payables (2010 - 2024) Analysis & Trends
TuHURA Biosciences' Change in Account Payables history runs 15 years deep, the most recent figure standing at -$4000.0 for Q3 2024.
- In Q3 2024, Change in Account Payables fell 110.0% year-over-year to -$4000.0; the TTM figure through Sep 2024 stood at -$314000.0 (up 54.43% YoY), while the FY2024 annual figure was -$248000.0, up 41.37% from the prior year.
- Change in Account Payables for Q3 2024 stood at -$4000.0, up from -$200000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $368000.0 in Q2 2020, with the low at -$368000.0 in Q1 2023.
- The 5-year median for Change in Account Payables is -$70000.0 (2021), against an average of -$35176.5.
- The sharpest annual moves came in 2021 and 2022: Change in Account Payables jumped 375.0% in 2021, then tumbled 509.62% in 2022.
- TuHURA Biosciences' Change in Account Payables stood at -$92000.0 in 2020, then jumped by 156.52% to $52000.0 in 2021, then sank by 509.62% to -$213000.0 in 2022, then gained by 29.58% to -$150000.0 in 2023, then surged by 97.33% to -$4000.0 in 2024.
- Business Quant data shows HURA's Change in Account Payables at -$4000.0 in Q3 2024, -$200000.0 in Q1 2024, and -$150000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Mar 31, 2024 | -200,000.00 |
| Mar 31, 2024 | -200,000.00 |
| Dec 31, 2023 | -150,000.00 |
| Dec 31, 2023 | -150,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Mar 31, 2023 | -368,000.00 |
| Mar 31, 2023 | -368,000.00 |
| Dec 31, 2022 | -213,000.00 |
| Dec 31, 2022 | -213,000.00 |
| Sep 30, 2022 | -148,000.00 |
| Sep 30, 2022 | -148,000.00 |
| Jun 30, 2022 | 263,000.00 |
| Jun 30, 2022 | 263,000.00 |
| Mar 31, 2022 | -85,000.00 |
| Mar 31, 2022 | -85,000.00 |
| Dec 31, 2021 | 52,000.00 |
| Dec 31, 2021 | 52,000.00 |